Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.3035
Abstract: 3035Background: Loss of CD19 expression is a major cause of limited durable B-ALL remission following CD19 CAR T cells, which might be overcome by utilization of dual CD19xCD22 CAR T cell targeting... read more here.
Keywords: efficacy scri; scri car19x22; cell product; car19x22 cell ... See more keywords